Homepage > Company > Media > Pharma News > 2022 > Merck Decides to Exercise Option Regarding PCV With Moderna

Merck Decides to Exercise Option Regarding PCV With Moderna

Merck has decided to exercise its option to develop and commercialize the personalized cancer vaccine (PCV) mRNA-4157/V940 with Moderna.

The two companies had inked a collaboration and licensing deal in 2016 to develop and commercialize novel personalized messenger RNA (mRNA) cancer vaccines. This deal was also expanded in 2018 to include shared antigen mRNA cancer vaccines.

The mRNA-4157/V940 vaccine candidate is being evaluated in combination with Merck’s blockbuster drug Keytruda (pembrolizumab) as adjuvant treatment for patients with high-risk melanoma in a phase 2 clinical trial. Moderna is conducting the clinical trial.

Under the terms of the agreement, Merck will pay Moderna $250 million to exercise its option for personalized cancer vaccines including mRNA-4157/V940.

October 13, 2022

https://www.fdanews.com/

Read also

Phase 3 trials of treatment combo for hepatitis D expected in 2025

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed ECLIPSE, to test its treatment combination of tobevibart and elebsi...

Breakthrough Therapy Designation Market Is Booming Worldwide 2024-2032

The Breakthrough Therapy Designation market has witnessed significant growth over the past decade, driven by advancements in technology, shifting consumer preferences, and increasing investments from ...

Veeva Commercial Summit: Increased investment in medical affairs by pharma companies

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

Remix

Remix Therapeutics to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)